IGMS IGM Biosciences: Forward P/S Multiple
IGM Biosciences, Inc. (IGMS) has completely shifted its strategic direction, pivoting away from oncology to focus on combating autoimmune pathologies. The current strategy is based on the implementation of IgM antibodies and support from Sanofi, which is reflected in the forward P/S valuation, where 0.30 represents the current metric. Business value growth now relies on progress in clinical trials and updated partnership data.
Comprehensive metric breakdowns and analytics for IGM Biosciences (IGMS)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- company liabilities and liquidity data:
- financial results and valuation multiples details:
IGMS - Net Financial Result|Projected Future Earnings IGM Biosciences, Inc.|IGMS - Price to Earnings Ratio|Forward P/E Multiple igmbio.com|IGMS - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple IGM Biosciences, Inc.|IGMS - Profit before interest, taxes and amortization|Earnings per share for the last twelve months IGM Biosciences|IGMS - Earnings per share for the last 12 months|Quarterly EPS earnings growth igmbio.com|IGMS - Net earnings per share growth this year|Earnings growth forecast for next year IGM Biosciences, Inc.
- revenue and sales proceeds data:
Summary company analytics:IGM Biosciences Inc. IGMS
Forward P/S measures an asset's market value relative to expected sales volume, allowing for an assessment of price volatility amplitude during external shocks. Analysis of the forward P/S chart for IGM Biosciences, Inc. (IGMS) reveals the capitalization's sensitivity to revenue growth rates, which is critical for IGM Biosciences, Inc. (IGMS) during the downsizing of its oncology division and the transition to organic R&D tests in partnership with Sanofi.
Analysis of competing companies
Forward P/S Multiple ARGX (argenx.com)|BioNTech Group (BNTX) - Market Cap to Future Revenue Ratio|ABIVAX - Forward P/S Multiple|ADMA - Forward P/S Multiple|Protagonist (PTGX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Immunovant Inc|Price-to-Projected Revenue Ratio Kiniksa Pharmaceuticals|Grifols Group (GRFS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Price-to-Projected Revenue Ratio CLDX (Celldex Therapeutics)|Price-to-Projected Revenue Ratio Aurinia Pharma AUPH|Forward Price to Sales BCRX|VERA: Forward Price-to-Revenue Multiple|Forward Price to Sales DNTH (Dianthus Therapeutics)|Pharvaris N.V. (PHVS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio AbCellera Biologics (ABCL)|TRML (Tourmaline Bio Inc) - Forward P/S Multiple|Market Cap to Projected Revenue PGEN (Intrexon)|Forward Price-to-Revenue Multiple PHAR (Pharming)|NKTR (Nektar) - Forward Price to Sales|Forward P/S Multiple UPB (upstreambio.com)|ZBIO (Zenas Biopharma Inc) - Future Price to Revenue|IMNM - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Gossamer Bio Inc GOSS|KALV: Forward P/S Multiple|Forward Price-to-Revenue Multiple Septerna Pharma|PVLA (Pieris Corp) - Forward P/S Multiple|Price-to-Projected Revenue Ratio SVRA|Forward P/S Multiple RIGL|Forward Price-to-Revenue Multiple AnaptysBio Corp ANAB|Astria Therapeutics Inc - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio enGene Holdings Inc. (ENGN)|RAPT Therapeutics Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aerovate Therapeutics, Inc.|ACRS (Aclaris Therapeutics) - Forward Price-to-Revenue Multiple|KYTX: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Tiziana Life Sciences|Cabaletta Bio, Inc (CABA) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple VTYX (Ventyx Biosciences)|Market Cap to Expected Sales Ratio theratech.com|Forward P/S Multiple AVTX (Avalo Therapeutics, Inc.)|Forward P/S Multiple Eledon Pharmaceuticals Inc. ELDN|AGEN: Forward Price-to-Revenue Multiple|Forward Price to Sales CLYM (Climb Bio, Inc)|ZURA: Forward P/S Multiple|aTyr Pharma, Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Adagene Inc.|IMA: Forward Price to Sales|Forward P/S Multiple STTK|Forward Price-to-Revenue Multiple Equillium Bio EQ|Price-to-Projected Revenue Ratio Connect Biopharma CNTB|IMUX - Forward Price-to-Revenue Multiple|ATRA - Price-to-Projected Revenue Ratio|InflaRx NV (IFRX) - Forward Price-to-Revenue Multiple|XFOR (X4 Pharmaceuticals Inc.) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Adicet Bio Inc. (ACET)|Price-to-Projected Revenue Ratio celularity.com|Forward Price-to-Revenue Multiple inmunebio.com (INMB)|Price-to-Projected Revenue Ratio Barinthus Biotherapeutics PLC (BRNS)|Market Cap to Expected Sales Ratio Kezar Life Sciences Inc.|SAB Biotherapeutics, Inc - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Akari Therapeutics, Plc (AKTX)|ENLV: Forward Price-to-Revenue Multiple|Forward Price to Sales QTTB (q32bio.com)|GeoVax Labs Inc (GOVX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Edesa|Price-to-Projected Revenue Ratio iBio, Inc.|Forward Price-to-Revenue Multiple carismatx.com (CARM)|Forward P/S Multiple XTLB|Forward Price-to-Revenue Multiple Bolt Bio BOLT|Forward P/S Multiple HCWB (HCW Biologics)|APVO: Market Cap to Projected Revenue|AIM - Price-to-Projected Revenue Ratio|ADTX - Forward P/S Multiple|GRI Bio (GRI) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple XORTX Therapeutics|Price-to-Projected Revenue Ratio Vyome Therapeutics|Market Cap to Projected Revenue REVB (Revelation Biosciences, Inc.)|Forward P/S Multiple INDP|Forward Price-to-Revenue Multiple Scinai Immunotherapeutics SCNI|Forward P/S Multiple CALI (CalciMedica)|AFMD - Forward Price-to-Revenue Multiple|ALLK: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio HOOKIPA Pharma HOOK|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Ocean Biomedical Corp (OCEA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward P/S Multiple thirdharmonicbio.com
